PLC ("TC BioPharm" or the "Company") (OTC: TCBPY) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

Cleantech leader Aymium defeated a challenge by Stora Enso to one of Aymium's patents (European Patent EP2697185) that provides exclusive rights to produce, sell and use bio-based materials for ...

CureVac's amended patent survives BioNTech's challenge as EPO upholds validity. A German court will decide on infringement in ...

Computer technology, which includes areas of AI such as machine learning and pattern recognition, led for the first time, with 16,815 patent applications in 2024. Electrical machinery, apparatus ...

The European Patent Office declared a patent owned by CureVac valid, after a challenge from drugmaker BioNTech, the company said on Thursday. U.S.-listed shares of Germany-based CureVac rose 11.8% in ...

Repirinast is the Company’s lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a ...

The European Patent Office’s latest report shows patent filings holding steady, with computer technology leading growth.

according to the annual Patent Index published on Tuesday by the European Patent Office (EPO). The EPO registered 199,264 patent applications last year, following three years of growth. Applications ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

CureVac (CVAC) announced that the European Patent Office has confirmed the validity of the company’s European patent EP 3 708 668 B1 subject to ...